The interventions with trial support, and the much longer list without

Constipation deserves separate treatment because it is the effect that responds best to unglamorous measures and the one most often left unmanaged. It is also the effect most likely to be dismissed as trivial by clinicians and experienced as intolerable by patients. Osmotic laxatives, adequate fluid, and attention to the fact that a much smaller food intake means a much smaller stool volume between them resolve a large proportion of cases, and none of that requires a new prescription or a dose change.

When the events happen

Gastrointestinal events in this class are concentrated in the escalation phase. Reported incidence rises in the days following a dose increase, declines over the subsequent weeks at an unchanged dose, and rises again at the next increment. Analyses that plot event onset against week show a series of peaks aligned to the escalation schedule rather than a flat burden across the trial.¹

Two things follow. The first is that the escalation phase is where discontinuation risk lives, which means the tolerability problem in this class is largely a titration problem. The second is that a symptom appearing eight months into stable dosing should not be attributed to the drug by default, because that is not where the drug-attributable events cluster.

There is a corollary that patients find useful and are rarely told. The worst week of a given dose is usually the first one. A person who has been unwell for four days after an increase is, on the published pattern, at the point where things typically begin to improve rather than at the beginning of a permanent state. That is a statement about a population and not a promise about an individual, and we put it that way deliberately.

Nausea: what is supported, what is reasonable

Randomised evidence for symptomatic nausea management specifically in this population is close to absent, so what follows is graded honestly. Reducing meal size and increasing meal frequency is mechanistically coherent given a stomach that empties slowly, and is universally recommended on that basis. Reducing fat and energy density has the same rationale, since fat slows emptying further. Avoiding recumbency after eating addresses reflux rather than nausea.

Pharmacological options are extrapolated from other settings. Ondansetron and related agents act on serotonergic emetic pathways and are widely prescribed here; there is no adequately powered trial of them in this context that we can find. Metoclopramide, a prokinetic, is mechanistically attractive and clinically awkward given its own adverse-effect profile and the fact that it opposes a therapeutic mechanism.

Ginger has small randomised trials in pregnancy and chemotherapy-related nausea and none here. It is inexpensive and low-risk, and readers should understand that the recommendation rests on transfer from other populations rather than on data in this one. The Journal would rather say that clearly than pad the list.²

Constipation: the tractable one

Constipation is the effect that responds most reliably to unglamorous measures and the one most often left unaddressed, partly because it is embarrassing and partly because it is graded as mild by clinicians and experienced as miserable by patients.

The measures with the clearest general evidence base are adequate fluid intake, an osmotic agent such as a polyethylene glycol preparation, and attention to fibre — which, as noted above, frequently falls disproportionately when appetite is suppressed. Stimulant laxatives work and are appropriate for short-term use. Bulking agents without adequate fluid can make matters worse and should be treated with more caution here than in the general population, because fluid intake on this treatment is often already low.

Two thresholds are worth naming. Constipation with abdominal distension, vomiting and absence of flatus is not constipation and needs urgent assessment. And constipation that persists after four weeks of adequate osmotic treatment is a reason to reassess rather than to escalate the laxative, since it may be the presentation of something else entirely.

The dehydration pathway, which is where the real harm is

The most consequential complication of this effect profile is not any single symptom. It is the sequence in which nausea reduces fluid intake, vomiting removes more, appetite suppression removes the substantial fraction of daily fluid that arrives in food, and volume depletion follows. Reports of acute kidney injury in association with this drug class are overwhelmingly of this kind rather than a direct nephrotoxic effect.

The risk is materially higher in three situations: concurrent diuretic or renin-angiotensin blockade, hot weather or heavy exertion, and any intercurrent illness with vomiting or diarrhoea. In each, the volume reserve that would ordinarily absorb a few poor days is not there.

The management is dull and effective. Fluid intake needs to be deliberate rather than appetite-led, because appetite is precisely the signal the drug has suppressed. A person who has stopped feeling thirsty in proportion to their needs is in the same situation as a person who has stopped feeling hungry in proportion to theirs, and for the same reason. This is the single point in the file where the Journal would say the standard advice is under-emphasised rather than over-confident.³

Five things about this effect profile nobody can answer

First, whether any symptomatic antiemetic strategy works better than placebo in this specific population. No adequately powered randomised trial exists that we can find.

Second, whether the dietary measures universally recommended have any measurable effect beyond the natural attenuation that occurs anyway at a fixed dose. Disentangling the two requires a design nobody has run.

Third, what predicts an individual tolerability ceiling. Nothing measurable at baseline does so usefully, which mirrors the situation for efficacy.

Fourth, how much of the perioperative risk is attributable to residual gastric content and how much to confounding by the conditions that lead people to these drugs. The available studies are mostly retrospective.

Fifth, whether gastrointestinal symptom burden predicts weight outcome. Analyses have looked, and the relationship is weaker than the folk model — which holds that suffering more means losing more — would predict.¹

Readers who know of trials answering any of the five should write to standards@compoundjournal.com. We would print the correction gladly.

A closing note on the market this publication covers. Everything above assumes the symptom is the molecule. For material sold for research use only it may be the content, the counter-ion, the reconstitution, or the endotoxin, and none of those is visible on a purity certificate. A person reasoning carefully about tolerability while holding a vial of unmeasured contents is reasoning carefully about the wrong variable.